BACKGROUND: Survival and prognostic factors for thin melanomas have been studied relatively little in population-based settings. This patient group accounts for the majority of melanomas diagnosed in western countries today, and better prognostic information is needed. OBJECTIVES: The aim of this study was to use established prognostic factors such as ulceration, tumour thickness and Clark's level of invasion for risk stratification of T1 cutaneous melanoma. METHODS: From 1990 to 2008, the Swedish Melanoma Register included 97% of all melanomas diagnosed in Sweden. Altogether, 13,026 patients with T1 melanomas in clinical stage I were used for estimating melanoma-specific 10- and 15-year mortality rates. The Cox regression model was used for further survival analysis on 11,165 patients with complete data. RESULTS: Ulceration, tumour thickness and Clark's level of invasion all showed significant, independent, long-term prognostic information. By combining these factors the patients could be subdivided into three risk groups: a low-risk group (67·9% of T1 cases) with a 10-year melanoma-specific mortality rate of 1·5% (1·2-1·9%); an intermediate-risk group (28·6% of T1 cases) with a 10-year mortality rate of 6·1% (5·0-7·3%); and a high-risk group (3·5% of T1 cases) with a 10-year mortality rate of 15·6% (11·2-21·4%). The high- and intermediate-risk groups accounted for 66% of melanoma deaths within T1. CONCLUSIONS: Using a population-based melanoma register, and combining ulceration, tumour thickness and Clark's level of invasion, three distinct prognostic subgroups were identified.
BACKGROUND: Survival and prognostic factors for thin melanomas have been studied relatively little in population-based settings. This patient group accounts for the majority of melanomas diagnosed in western countries today, and better prognostic information is needed. OBJECTIVES: The aim of this study was to use established prognostic factors such as ulceration, tumour thickness and Clark's level of invasion for risk stratification of T1 cutaneous melanoma. METHODS: From 1990 to 2008, the Swedish Melanoma Register included 97% of all melanomas diagnosed in Sweden. Altogether, 13,026 patients with T1 melanomas in clinical stage I were used for estimating melanoma-specific 10- and 15-year mortality rates. The Cox regression model was used for further survival analysis on 11,165 patients with complete data. RESULTS: Ulceration, tumour thickness and Clark's level of invasion all showed significant, independent, long-term prognostic information. By combining these factors the patients could be subdivided into three risk groups: a low-risk group (67·9% of T1 cases) with a 10-year melanoma-specific mortality rate of 1·5% (1·2-1·9%); an intermediate-risk group (28·6% of T1 cases) with a 10-year mortality rate of 6·1% (5·0-7·3%); and a high-risk group (3·5% of T1 cases) with a 10-year mortality rate of 15·6% (11·2-21·4%). The high- and intermediate-risk groups accounted for 66% of melanoma deaths within T1. CONCLUSIONS: Using a population-based melanoma register, and combining ulceration, tumour thickness and Clark's level of invasion, three distinct prognostic subgroups were identified.
Authors: Phyllis A Gimotty; Ronald Shore; Nancy L Lozon; Jeanne Whitlock; Sidan He; Fawn D Vigneau; Lois Dickie; David E Elder; Xiaowei Xu; Ann G Schwartz; DuPont Guerry Journal: J Invest Dermatol Date: 2016-06-25 Impact factor: 8.551
Authors: Eric J Stanelle; Klaus J Busam; Barrie S Rich; Emily R Christison-Lagay; Ira J Dunkel; Ashfaq A Marghoob; Allan Halpern; Daniel G Coit; Michael P La Quaglia Journal: J Pediatr Surg Date: 2015-03-14 Impact factor: 2.545
Authors: Alexander M M Eggermont; Domenico Bellomo; Suzette M Arias-Mejias; Enrica Quattrocchi; Sindhuja Sominidi-Damodaran; Alina G Bridges; Julia S Lehman; Tina J Hieken; James W Jakub; Dennis H Murphree; Mark R Pittelkow; Jason C Sluzevich; Mark A Cappel; Sanjay P Bagaria; Charles Perniciaro; Félicia J Tjien-Fooh; Barbara Rentroia-Pacheco; Renske Wever; Martin H van Vliet; Jvalini Dwarkasing; Alexander Meves Journal: Eur J Cancer Date: 2020-10-05 Impact factor: 9.162
Authors: Peter D Baade; Patrick Royston; Philipa H Youl; Martin A Weinstock; Alan Geller; Joanne F Aitken Journal: BMC Cancer Date: 2015-01-31 Impact factor: 4.430
Authors: Lazaro Hiram Betancourt; Jeovanis Gil; Yonghyo Kim; Viktória Doma; Uğur Çakır; Aniel Sanchez; Jimmy Rodriguez Murillo; Magdalena Kuras; Indira Pla Parada; Yutaka Sugihara; Roger Appelqvist; Elisabet Wieslander; Charlotte Welinder; Erika Velasquez; Natália Pinto de Almeida; Nicole Woldmar; Matilda Marko-Varga; Krzysztof Pawłowski; Jonatan Eriksson; Beáta Szeitz; Bo Baldetorp; Christian Ingvar; Håkan Olsson; Lotta Lundgren; Henrik Lindberg; Henriett Oskolas; Boram Lee; Ethan Berge; Marie Sjögren; Carina Eriksson; Dasol Kim; Ho Jeong Kwon; Beatrice Knudsen; Melinda Rezeli; Runyu Hong; Peter Horvatovich; Tasso Miliotis; Toshihide Nishimura; Harubumi Kato; Erik Steinfelder; Madalina Oppermann; Ken Miller; Francesco Florindi; Qimin Zhou; Gilberto B Domont; Luciana Pizzatti; Fábio C S Nogueira; Peter Horvath; Leticia Szadai; József Tímár; Sarolta Kárpáti; A Marcell Szász; Johan Malm; David Fenyö; Henrik Ekedahl; István Balázs Németh; György Marko-Varga Journal: Clin Transl Med Date: 2021-07